Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix s Q4 Revenues Increase 3.5 Percent, Beating Earlier Projection Cuts; Profits Tumble

NEW YORK, Jan. 27 (GenomeWeb News) - Affymetrix reported yesterday a 3.5-percent increase in revenues for the fourth quarter of 2005.


Total revenue for the fourth quarter inched up to $111.5 million from $107.7 million during the year-ago period.


Affymetrix's Q4 revenues were approximately $6 million dollars above its last projection of $105 million. The company had cut its fourth-quarter revenue projection twice since the fall of 2005, citing "growing pains" as it brought new products into potential markets.


Affy's fourth-quarter profit fell 8.2 percent to $24.8 million, or $0.35 per share, from $27.1 million, or $0.41 per share, during the fourth quarter of 2004.


R&D spending during the period decreased to $19.7 million from $20.5 million year-over-year.


As of Dec. 31, 2005, Affymetrix had $100 million in cash and cash equivalents.


For fiscal 2006, Affymetrix predicted product and product-related revenue of about $400 million, and total revenue of about $420 million.


For the first quarter of 2006, Affy projected product and product-related revenue of $87 million, and total revenue of about $91 million.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.